Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
Hematological toxicity is the most common adverse event after chimeric antigen receptor
(CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …
(CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …
[HTML][HTML] Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy
K Wudhikarn, MA Perales - Bone Marrow Transplantation, 2022 - nature.com
CD19-targeted chimeric antigen receptor (CAR) T-cell becomes a breakthrough therapy
providing excellent remission rates and durable disease control for patients with …
providing excellent remission rates and durable disease control for patients with …
CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma
Hematotoxicity represents a frequent chimeric antigen receptor (CAR) T-cell–related
adverse event and remains poorly understood. In this multicenter analysis, we studied …
adverse event and remains poorly understood. In this multicenter analysis, we studied …
[HTML][HTML] The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
K Rejeski, A Perez, G Iacoboni, O Penack… - … for ImmunoTherapy of …, 2022 - ncbi.nlm.nih.gov
Background CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) represents a
promising treatment modality for an increasing number of B-cell malignancies. However …
promising treatment modality for an increasing number of B-cell malignancies. However …
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
CD19 CAR T-cells represent a practice-changing treatment modality for advanced B-cell
malignancies. However, refractory cytopenias have emerged as a potentially life-threatening …
malignancies. However, refractory cytopenias have emerged as a potentially life-threatening …
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
K Rejeski, A Perez, G Iacoboni, V Blumenberg… - Science …, 2023 - science.org
Prolonged cytopenias after chimeric antigen receptor (CAR) T cell therapy are a significant
clinical problem and the underlying pathophysiology remains poorly understood. Here, we …
clinical problem and the underlying pathophysiology remains poorly understood. Here, we …
[HTML][HTML] The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple …
Abstract Background BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment
landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side …
landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side …
Infectious complications of CAR T-cell therapy: a clinical update
AG Stewart, AS Henden - Therapeutic Advances in Infectious …, 2021 - journals.sagepub.com
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary treatment modality used to
treat haematological malignancies. Lymphocytes are engineered to produce CARs directed …
treat haematological malignancies. Lymphocytes are engineered to produce CARs directed …
Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL
The advent of chimeric antigen receptor (CAR) T-cell therapy has revolutionized the
treatment landscape of refractory B-cell malignancies. Real-world evidence has highlighted …
treatment landscape of refractory B-cell malignancies. Real-world evidence has highlighted …
CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy
K Mullanfiroze, A Lazareva, J Chu, L Williams… - Blood …, 2022 - ashpublications.org
Adoptive immunotherapy with chimeric antigen receptor (CAR) T-cell therapy has improved
outcomes in patients with relapse/refractory B-acute lymphoblastic leukemia (r/r B-ALL) …
outcomes in patients with relapse/refractory B-acute lymphoblastic leukemia (r/r B-ALL) …